ChiCTR2300067632 版本V1.0 版本创建时间2023/05/12 20:21:22 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300067632 

最近更新日期:

Date of Last Refreshed on:

2023-01-15 21:39:34 

注册时间:

Date of Registration:

2023-01-15 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

入住ICU的新冠病毒感染患者呼吸支持和镇静镇痛现状调查:一项一日横断面研究

Public title:

A One-Day Prospective National Observational Study on Respiratory support and Sedation-Analgesia of Patients Admitted to the Intensive Care Unit With SARS-CoV-2 infection

注册题目简写:

English Acronym:

研究课题的正式科学名称:

入住ICU的新冠病毒感染患者呼吸支持和镇静镇痛现状调查:一项一日横断面研究

Scientific title:

A One-Day Prospective National Observational Study on Respiratory support and Sedation-Analgesia of Patients Admitted to the Intensive Care Unit With SARS-CoV-2 infection

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐继前 

研究负责人:

尚游 

Applicant:

Jiqian Xu 

Study leader:

You Shang 

申请注册联系人电话:

Applicant telephone:

+8619947698091

研究负责人电话:

Study leader's
telephone:

+8615972127819

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xjq5456.good@163.com

研究负责人电子邮件:

Study leader's E-mail:

you_shanghust@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

湖北省武汉市江汉区解放大道1277号

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖北省武汉市江汉区解放大道1277号

研究负责人通讯地址:

湖北省武汉市江汉区解放大道1277号

Applicant address:

1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China

Study leader's address:

1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China

申请注册联系人邮政编码:

Applicant postcode:

430022

研究负责人邮政编码:

Study leader's postcode:

430022

申请人所在单位:

华中科技大学同济医学院附属协和医院

Applicant's institution:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

研究负责人所在单位:

华中科技大学同济医学院附属协和医院

Affiliation of the Leader:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[2023]伦审字(0027-01)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

华中科技大学同济医学院附属协和医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

伦理委员会批准日期:

Date of approved by ethic committee:

2023-01-13 00:00:00

伦理委员会联系人:

侯晓华

Contact Name of the ethic committee:

Xiaohua Hou

伦理委员会联系地址:

湖北省武汉市江汉区解放大道1277号

Contact Address of the ethic committee:

1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

027-85726375

伦理委员会联系人邮箱:

Contact email of the ethic committee:

whunionlunli@126.com

研究实施负责(组长)单位:

华中科技大学同济医学院附属协和医院

Primary sponsor:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

研究实施负责(组长)单位地址:

湖北省武汉市江汉区解放大道1277号

Primary sponsor's address:

1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北省

市(区县):

武汉市

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

华中科技大学同济医学院附属协和医院

具体地址:

湖北省武汉市江汉区解放大道1277号

Institution
hospital:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Address:

1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China

经费或物资来源:

华中科技大学同济医学院附属协和医院青年高层次人才支持计划

Source(s) of funding:

The Youth High-Level Talent Support Program of Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

研究疾病:

COVID-19  

Target disease:

Coronavirus Disease 2019

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

主要研究目的:明确入住ICU的新冠病毒感染患者呼吸支持手段、呼吸机参数设定、镇静镇痛药物选择的日常情况。 次要研究目的:调查入住ICU的新型冠状病毒肺炎患者在研究当天生命体征、临床表现、实验室检查及治疗情况。  

Objectives of Study:

The primary aim of the study is to identify what is the current daily practice regarding Respiratory support and sedation/analgesia in the management of Patients Admitted to the Intensive Care Unit With SARS-CoV-2 infection; The secondary aim of the study is to investigate the demographic information, clinical characteristics, vital signs, complications, laboratory values, and clinical therapy of the patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

年龄18~岁(包括18 岁)
新型冠状病毒(SARS-CoV-2)核酸检测阳性;
入住ICU

Inclusion criteria

Patients aged ≥ 18 years
Confirmed diagnosis of SARS-CoV-2 infection by a positive result on a RT-PCR
Admission to the ICU

排除标准:

年龄< 18岁;
预计患者24h内死亡;

Exclusion criteria:

Patients aged< 18 years
Patients who deceased within 24 h during ICU admission

研究实施时间:

Study execute time:

From 2023-01-13 00:00:00 To 2024-01-13 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-01-13 00:00:00 To 2024-01-13 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

500

Group:

Case series

Sample size:

干预措施:

N//A

干预措施代码:

N//A

Intervention:

N//A

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北省 

市(区县):

武汉市 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

华中科技大学同济医学院附属协和医院 

单位级别:

三级甲等 

Institution
hospital:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南省 

市(区县):

郑州市 

Country:

China

Province:

Henan

City:

Zhengzhou

单位(医院):

郑州大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The first affiliated hospital of Zhengzhou university

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南 

市(区县):

郑州 

Country:

China

Province:

Henan

City:

Zhengzhou

单位(医院):

河南省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Henan Provincial People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北省 

市(区县):

襄阳市 

Country:

China

Province:

Hubei

City:

Xiangyang

单位(医院):

襄阳市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Xiangyang Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属中山医院 

单位级别:

三级甲等 

Institution
hospital:

Zhongshan Hospital, Fudan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

陕西 

市(区县):

西安市 

Country:

China

Province:

Shanxi

City:

xi'an

单位(医院):

西安交通大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Xi'an Jiaotong University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

安徽省 

市(区县):

合肥市 

Country:

China

Province:

An'hui

City:

Hehui

单位(医院):

中国科学技术大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

First Affiliated Hospital of University of Science and Technology of China

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏省 

市(区县):

南京市 

Country:

China

Province:

Jiang'su

City:

Nanjing

单位(医院):

南京医科大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

First Hospital Affiliated to Nanjing Medical University.

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

呼吸支持手段、呼吸机参数设定、镇静镇痛药物

指标类型:

主要指标

Outcome:

Respiratory support, sedation/analgesia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生命体征、临床表现、实验室检查

指标类型:

次要指标

Outcome:

vital signs, clinical manifestations, laboratory examination and treatment of patients

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

与主要研究者联系,经过研究者同意后开放共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact with the lead researchers and then sharing with the consent

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

研究当天,研究者对入住ICU的所有新冠病毒感染患者进行全天筛查。然后研究者必须完成eCRF的以下七个部分:1.患者在研究当日上午8点的一般信息,如性别、年龄、身高、体重、发病日期、入院日期、转入ICU日期。2. 既往病史。3.研究当日上午8点,生命体征,呼吸和循环支持在。4. 研究当日上午8点的实验室检查结果。5. 呼吸机支持方式与参数测定,以及呼吸力学测定,6.镇静、镇痛及器官功能。7. 在研究期间发生的重要事件。在调查人员输入数据期间,研究团队在网上进行了可信性和完整性检查。在数据收集之前,eCRF详细定义了每个变量。 主要包括5部分,基本信息、调查当日的化验指标、调查当日呼吸支持现状、镇痛镇静现状、基本治疗与主要器官损伤情况;

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

On the study day, the investigator screened all the COVID-19 patients admitted to the ICU for the whole day. The investigator had to complete the following seven sections of the eCRF: 1. general characteristics at the 8am February 24th, such as gender, age, stature, weight, date of onset, date of the hospitalization, the ICU admission date. 2. Past medical history. 3. Vital signs, respiratory and circulation support at the 8am February 24th. 4. The laboratory values at 8am February 24th. 5. The respiratory support, breathing pattern, parameter setting and assessing respiratory mechanics. 6. The sedation, analgesia and the organ function. 7. The events in the study time. During date entry by the investigators, the study team plausibility and completeness checks were performed online. Each variable was defined in detail in the eCRF before the data collection.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-01-15 21:39:35